Formación de hueso nuevo y Espondilitis Anquilosante
Keywords:
espondilitis anquilosante, sindesmofitosAbstract
La formación de hueso nuevo en la espondilitis anquilosante es uno de los temas de mayor interés en la patogenia de la enfermedad y al cual se le ha prestado gran atención en el transcurso de los últimos años, revolucionado la opinión inicial de la patogenia de la enfermedad y de que el tratamiento de la inflamación de la entesis con los anti TNF lograría el control de la formación de hueso nuevo (sindesmofitos y la anquilosis ósea) que se produce en la espondilitis anquilosante. Es real y está demostrado que el tratamiento con anti TNF prácticamente logran controlar el proceso inflamatorio, pero no ocurre lo mismo con la formación de hueso nuevo en la Espondilitis Anquilosante.
Downloads
References
Yang Mei, Faming Pan, Jing Gao, Rui G. Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis. Clin Rheumatol 2011; 30: 269- 73.
Aguado Acín P. Lo que el clínico debe saber sobre los mecanismos de conexión entre la inflamación y la formación de hueso. ¿Es suficiente el bloqueo de la inflamación para prevenir la osificación? Reumatol Clin.2010; 6(S1):28–32.
Mc Gonagle D, Wakefield RJ, Tan AL, D’Agostino M A,Toumi H, Hayashi K. Distinct topography of erosion and new bone formation in achilles tendon enthesitis. Implications for understanding the link between inflammation and bone formation in spondylarthritis.Arthritis Rheum.2008; 58: 2694-9.
Boyle W J,Simonet WS,Lacey DL. Osteoclast differentiation and activation. Nature. 2003; 423: 337- 42.
Hofbauer LC, Schoppet M. Clinical implications of the Osteoprotegerin/RANKL/RANK System for bone and vascular diseases. J AMA. 2004; 292: 490- 5.
Braun J, Sieper J: Ankylosing spondylitis. Lancet 2007, 369: 1379- 90.
Walsh C,Gravallese EM. Bone loss in inflammatory arthritis: mechanisms and treatment strategies.Curr Opin Rheumatol. 2004; 16: 419– 27.
Vandooren B, Cantaert T, Noodenbos T, Tak PP, Baeten D. The abund synovial expression of the RANKL/RANK/Osteoprotegerin system in peripheral spondyloarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008; 58: 718– 29.
Van der Heijde D, Landewe R, Einstein S. Radiographic progression of ankylosingspondylitis after up to two years of treatment with etanercept.Arthritis Rheum 2008, 58:1324- 31.
Van der Heijde D, Landewe R, Baraliakos X.: Radiographicfindings following two years of infliximab therapy inpatients with ankylosing spondylitis. Arthritis Rheum 2008, 58: 3063- 70.
Van der Heijde D, Landewe R, Maksymowych W. Adalimumab (HUMIRA®) therapy for Ankylosing spondylitisover 2 years does not demonstrate inhibition of radiographicprogression compared with a historical control group. Arthritis Rheum 2008, 58: 413-22.
Wanders A, van der Heijde D, Landewe R, Behier JM, Calin A, Olivieri I, Zeidler H, Dougados M: Nonsteroidal antiinflammatorydrugs reduce radiographic progression in patients with ankylosingspondylitis: a randomized clinical trial. Arthritis Rheum. 2005; 52: 1756- 65.
Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts and prospects. J Clin Invest. 2005; 115: 3318– 25.
Tam, LS, Gu, J, David Y.Pathogenesis of ankylosing spondylitis. Nat. Rev. Rheumatol.2010; 6: 399–405.
Lories, R. J, Luyten, F. P. Bone morphogenetic protein signaling in joint homeostasis and disease. Cytokine Growth Factor Rev. 2005; 16: 287– 98.
Winkler, D. G. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J. Biol. Chem. 2004; 279: 36293– 98.
De Vlam K, Lories RJ, Luyten FP: Mechanisms of pathologic new bone formation. Curr Rheumatol Rep. 2006; 8:332-7.
Macsai CE, Foster BK, Xian CJ: Roles of Wnt signaling in bone growth, remodeling, skeletal disorders and fracture repair. J Cell Physiol. 2008; 215: 578- 87.
Lories R.J.U, Luyten F. P, de Vlam K. Progres in spondiloarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Research & Therapy. 2009; 11: 221-28.
Lories RJU, Derese I, Luyten FP: Modulation of Bone Morphogenetic Protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest. 2005; 115:1571- 79.
Schett, G., Zwerina, J, David, J. P. The role of Wnt proteins in arthritis. Nat. Clin. Pract.Rheumatol. 2008; 4: 473- 80.
Chen Y, Whetstone HC, Youn A. Beta-catenin signaling pathway is crucial for bonemorphogenetic protein 2 to induce new bone formation. J BiolChem 2007, 282:526-33.
Tamamura Y, Otani T, Kanatani N, Developmental regulation of Wnt/betacateninsignals is required for growth plate assembly, cartilageintegrity, and endochondral ossification. J Biol Chem. 2005; 280: 19185- 95.
Van Bezooijen, R. L. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 2004; 199: 805-14.
Diarra D, Stolina M, Polzer K,Zwerina J, Ominsky MS, Dwyer D,etal. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007; 13: 156- 63.
Daoussis, D. Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. ArthritisRheum. 2010; 62: 150- 58.
Appel H, Ruiz-Heiland G, Listing J, Zwerina J,Herrmann M, Mueller R, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis Artritis Rheum. 2009; 60: 3257-62.
Maksymowych, W. P. Disease modification in ankylosing spondylitis. Nat. Rev. Rheumatol. 2010; 6: 75- 81.
Lories R J U, DereseI ,De Bari C, Luyten FP. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis & Rheum.2007; 56:489-97.
Andreu, José Luis, Teresa Otón, and Jesús Sanz. "Terapia anti-TNFα en espondilitis anquilosante: control sintomático y modificación del daño estructural." Reumatología Clínica 7.1 (2011): 51-55.
Maksymowych WP, Chiowchanwisawakit P, ClareT, Pedersen SJ, Ostergaard M, Lambert RGW. Inflammatory lesions of the spine of magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Evidence of a relationship between inflammation and new bone formation. Arthritis Rheum.2009; 60:93–102.
Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J: Effects of infliximab on markers of inflammationand bone turnover and associations with bone mineraldensity in patients with ankylosing spondylitis. Ann Rheum Dis. 2009; 68: 175-82.
Woo JH, Lee HJ, Sung IH, Kim TH: Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol. 2007; 34:1753- 59.
Appel H, Janssen L, Listing J, Heydrich R, Rudwaleit M, Sieper J: Serum levels of biomarkers of bone and cartilage destructionand new bone formation in different cohorts of patients withaxial spondyloarthritis with and without tumor necrosis factoralphablocker treatment. Arthritis Res Ther. 2008; 10: 125-36.
Published
How to Cite
Issue
Section
License
Warning of rights of author
The authors that publish in this journal agree with the following terms:
The authors conserve the rights of author and concede to the journal the right of the first publication, fulfilling with the license Creative Commons Attribution License that allows to others share the work with recognition of the authorship of their articles, and the initial publication in this journal.
The authors can establish separately additional agreements for the no exclusive distribution of the version of the work published in the journal (for example, situate it in an institutional repository, in a personal blog or publish it partial or totally in a book), with a recognition of their initial publication in this journal.
To be able to send the manuscript or part of him passed three months of published, for his evaluation to other publishers, identifying it or not with the same title; whenever allusion is made to our journale and know it the new publisher.
The publishing committee of the Cuban Journal of Rheumatology authorizes to other publishers, to reproduce the articles published in our magazine, whenever it indicate the origin of the same.
The authors should send a document in Office Word application format through the electronic address of the magazine with a similar format to that we include next:
---------------------------------------------------------------------------------------------------------------------
Statement of authorship and cede of articles for the publication of the scientific work in the Cuban Journal of Rheumatology
Date:
Those who subscribe certify that are the authors of the work:
Of this form communicate the originality of our article clearing that the concepts and knowledges of other authors that have included in the text of the article, have been quoted properly in the bibliography.
We do proof besides that the article in question is original and has not been published, total neither partially, in another journal.
To be approved for his publication in the Cuban Journal of Rheumatology, do secession of the rights of publication to the same one through the method that realizes it usually.
In front of any catchword that exist by the article that send to evaluate, relieve of of the responsibility to the Cuban Journal of Rheumatology holding us responsible with all the difficulties that can berelated by any situation.
We include to continuation the name and the signature of all authors and collaborators of this article.
Name: Signature:
